Artificial intelligence (AI) focused RevelAi Health and global medical technology company Zimmer Biomet Holdings, Inc. are partnering together to deliver generative AI orthopedic solutions.
Zimmer Biomet Partners With Patient Care AI Company
1 min read Premium comments
#zimmerbiometSecondary#revelaihealth
The partnership includes a multi-year co-marketing agreement. The focus of the partnership will be, according to Zimmer Biomet, “to commercialize generative artificial intelligence (AI)-powered engagement solutions.” These solutions will be dedicated to “value-based orthopedic care and health equity.”
Under the terms of the agreement, Zimmer Biomet will commercialize a number of products and services from the RevelAi Health portfolio. This includes RevelAi Health’s patient care-management platform and care team dashboard for providers. Zimmer Biomet will also commercialize any of RevelAi Health’s future products or services.
RevelAi Health develops software as a service (SAAS) health technology with an emphasis on generative AI population health solutions. Its solutions have been created with a focus on helping healthcare providers deliver value-based care. Its solutions also help healthcare providers meet many of the requirements of the Centers for Medicare & Medicaid Services (CMS). This includes patient reported outcome measures and social drivers of health screening.
RevelAi Health’s portfolio also includes a patient care management system. This system is designed to improve patient engagement and care workflow. It utilizes both text messaging and a voice agent to enhance patient care. The voice agent is actually guided by a clinician to enhance the patient’s experience.
RevelAi Health’s CEO Christian Péan M.D., M.S., is an orthopedic trauma surgeon at Duke University School of Medicine. Dr. Péan commented, “Leveraging generative AI to streamline clinical care workflows while addressing socio-demographic disparities is a unique opportunity to drive equitable value-based outcomes.”
Dr. Péan continued, “Our AI-enabled asynchronous care model delivers personalized, timely, and effective patient care while reducing clinician burnout. Our collaboration with Zimmer Biomet is a significant step towards ensuring that every patient receives the care they deserve.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.